CWBRライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 04:10):

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases...

Stats
本日の出来高	681.00
平均出来高	2 000.00
時価総額	2.56M
EPS	$0 ( 2024-03-26 )
次の収益日	( $0 ) 2024-05-17
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.200
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2022-08-01	Biunno Jeffrey Francis	Buy	26 203	Common Stock
2022-08-01	Sarret Joseph J.	Buy	131 017	Common Stock
2022-07-11	Tozzo Stephanie	Buy	200 000	Stock Option (Right to buy)
2022-07-11	Tozzo Stephanie	Buy	0
2021-12-29	Biunno Jeffrey Francis	Buy	75 000	Stock Option (Right to buy)

INSIDER POWER
100.00
Last 94 transactions
Buy: 7 451 858 \| Sell: 253 700

CohBar Inc 相関

10 最も正の相関
YJ	0.911
EFOI	0.867
PRVB	0.865
SMED	0.863
CXSE	0.859
PXLW	0.857
HLBZ	0.856
PCTTU	0.849
MCHI	0.848
WB	0.839

10 最も負の相関
HZNP	-0.876
PPBT	-0.834
SLGG	-0.829
LEDS	-0.81

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

CohBar Inc 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-4.13

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-4.13

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-9.51

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-10.00

Financial Reports:

No articles found.

CohBar Inc

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.